Insights / Press Releases
Keep up with Primrose Bio’s
latest news
Primrose Bio Names Drew Burch as CEO
San Diego, Calif. October 1, 2025 – Primrose Bio, Inc. (“Primrose”) announced today the appointment of Andrew “Drew” Burch as its Chief Executive Officer, and member of the Board of Directors. Drew...
Primrose Bio Launches Prima RNApols™ ExTend, an RNA Polymerase for Long-Template mRNA Manufacturing
Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic...
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine...
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines
Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology...
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines,...
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for...
